| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
Aminothiazole itself is not a drug and does not have a specific biological target. However, the thiazole ring system is a common pharmacophore in medicinal chemistry, and aminothiazole derivatives exhibit a wide range of biological activities. Aminothiazole-containing compounds target various enzymes and receptors, including kinases, proteases, and neurotransmitter receptors. The amino group provides a handle for further derivatization to enhance biological activity and selectivity.
|
|---|---|
| ln Vitro |
In the investigation of hyperthyroidism, aminothiazoles have antimicrobial properties and inhibit the thyroid [1]. Antibacterial and anti-tuberculosis medications can be made with aminothiazole [3].
Aminothiazole itself is not a pharmacologically active drug and does not have conventional in vitro biological activity. However, aminothiazole derivatives have been shown to exhibit various biological activities, including antibacterial, antifungal, antiviral, anti-inflammatory, and anticancer properties. The in vitro activity of aminothiazole derivatives depends on the specific substitutions on the thiazole ring and the target being studied. |
| ln Vivo |
As a chemical intermediate rather than a drug, Aminothiazole does not have intrinsic in vivo biological activity. However, aminothiazole derivatives have been studied in vivo for their therapeutic potential. For example, some aminothiazole-containing compounds have been shown to have antitumor activity in animal models. The in vivo activity of aminothiazole derivatives depends on their specific chemical structure and pharmacokinetic properties.
|
| Enzyme Assay |
In vitro enzyme inhibition assays for aminothiazole derivatives typically involve measuring the activity of the target enzyme in the presence of varying concentrations of the compound. The compound is dissolved in an appropriate solvent and diluted in assay buffer. The enzyme activity is measured using a suitable substrate and detection method, such as spectrophotometry, fluorometry, or radiometry. The IC50 value is determined from dose-response curves.
|
| Cell Assay |
Aminothiazole itself is not used in cell-based assays as a drug. However, aminothiazole derivatives can be evaluated for their biological activity in cell-based assays. Cells are treated with the aminothiazole derivative at various concentrations, and cell viability, proliferation, or other relevant endpoints are measured. The specific assay format depends on the biological activity being investigated.
|
| Animal Protocol |
Aminothiazole is a chemical intermediate and is not used as a drug in animal studies. However, aminothiazole derivatives that show promising in vitro activity may be evaluated in animal models for their efficacy and safety. The specific animal model and study design depend on the therapeutic indication being investigated. The compound is typically administered orally or parenterally.
|
| ADME/Pharmacokinetics |
Aminothiazole is a small, hydrophilic molecule with a molecular weight of 100.14 g/mol. As a chemical intermediate, its pharmacokinetic properties are not typically characterized in detail. However, aminothiazole is expected to be well-absorbed after oral administration and to be excreted in the urine. Aminothiazole-containing drugs have diverse pharmacokinetic properties depending on their specific chemical structure.
|
| Toxicity/Toxicokinetics |
Aminothiazole is a chemical intermediate and is not used as a therapeutic agent. Its toxicity is primarily relevant in the context of industrial handling. Aminothiazole can cause skin and eye irritation. Inhalation of aminothiazole dust may cause respiratory irritation. The compound should be handled with appropriate personal protective equipment. The toxicity of aminothiazole derivatives varies depending on their specific chemical structure and target.
|
| References |
|
| Additional Infomation |
2-Aminothiazole is a light brown crystal or brown granular solid. (NTP, 1992)
1,3-Thiazole-2-amine is a primary amino compound, a compound in which 1,3-thiazole is substituted with an amino group at the 2-position. It is a type of 1,3-thiazole compound and a primary amino compound. Aminothiazole is a heterocyclic building block widely used in organic synthesis and medicinal chemistry. It serves as a precursor for the synthesis of various pharmaceutical compounds, including the antibiotics cephalosporins and penicillins, the antiviral agent ritonavir, and the anticancer drug dasatinib. Aminothiazole is also used in the synthesis of dyes, agrochemicals, and other industrial chemicals. The compound is not an FDA-approved drug and is not commercially available as a pharmaceutical product. |
| Molecular Formula |
C3H4N2S
|
|---|---|
| Molecular Weight |
100.14226
|
| Exact Mass |
100.009
|
| CAS # |
96-50-4
|
| Related CAS # |
146614-45-1;57530-25-3 (mononitrate);63589-20-8 (sulfate[1:1])
|
| PubChem CID |
2155
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
216.4±9.0 °C at 760 mmHg
|
| Melting Point |
91-93 °C(lit.)
|
| Flash Point |
84.7±18.7 °C
|
| Vapour Pressure |
0.1±0.4 mmHg at 25°C
|
| Index of Refraction |
1.645
|
| LogP |
0.38
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
6
|
| Complexity |
48.1
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RAIPHJJURHTUIC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H4N2S/c4-3-5-1-2-6-3/h1-2H,(H2,4,5)
|
| Chemical Name |
1,3-thiazol-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~998.60 mM)
DMSO : ≥ 50 mg/mL (~499.30 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (24.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (24.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.9860 mL | 49.9301 mL | 99.8602 mL | |
| 5 mM | 1.9972 mL | 9.9860 mL | 19.9720 mL | |
| 10 mM | 0.9986 mL | 4.9930 mL | 9.9860 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02145312 | Unknown status | Drug: BYL719 | Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck |
Yonsei University | 2016-10-01 | Phase 2 |
| NCT02273219 | Completed | Drug: AEB071 Drug: BYL719 |
Uveal Melanoma | Columbia University | 2014-11-19 | Phase 1 |
| NCT03292250 | Completed | Drug: BYL719 Drug: Poziotinib Drug: Nintedanib |
HNSCC Head and Neck Neoplasms |
Seoul National University Hospital | 2017-09-10 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
